Pertussis toxin

A protein endotoxin that catalyzes ADP-ribosylation of guanine nucleotide-binding regulatory proteins. The holotoxin has five dissimilar subunits S-1, S-2, S-3, S-4, and S-5, in a molar ratio of 1:1:1:2:1, S-1 (A protomer) is responsible for the enzymatic activity of the toxin, and S-2, S-3, S-4, and S-5 form the B oligomer which is responsible for the toxins binding to the cell surface. NOTE: This product is not activated, hence for use in cell-free systems, activation is required.

A protein endotoxin that catalyzes ADP-ribosylation of guanine nucleotide-binding regulatory proteins. Used in the study of adenylate cyclase regulation and the role of G_i proteins. The holotoxin has five dissimilar subunits S-1, S-2, S-3, S-4, and S-5, in a molar ratio of 1:1:1:2:1. S-1 (a protomer) is responsible for the enzymatic activity of the toxin, and the other subunits (2-5) form the B oligomer which is responsible for the toxin′s binding to the cell surface. Note: This product is not activated. If used with an intact cell system, the cells will activate the toxin. If used in a cell-free system, product may be activated by the methods of either Kaslow and Burns or Moss at al.(see references).

Pertussis Toxin, Bordetella pertussis, Glycerol Solution, CAS 70323-44-3, is a protein endotoxin that catalyzes ADP-ribosylation of guanine nucleotide-binding regulatory proteins.

≤1 ng/ml as determined in a clustering assay using CHO cells line

Primary Target
Guanine nucleotide-binding regulatory proteins

Product does not compete with ATP.

Target IC₅₀: ≤1 ng/ml as determined in a clustering assay using CHO cells line

Toxicity: Toxic (F)

In 500 mM NaCl, 50 mM Tris, 10 mM glycine, 50% glycerol, pH 7.5.

A uniform suspension may be achieved by gentle mixing prior to use.

Five distinct bands by SDS-PAGE

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Fryer, M.W. 1992. Neurosci. Lett.146, 84.
Gierschik, P. 1992. Curr. Topics Microbiol. Immunol.175, 69.
Harada, J., et al. 1992. Eur. J. Pharmacol.227, 301.
Hausman, S.Z., and Burns, D.L. 1992. J. Biol. Chem.267, 13735.
Kaslow, H.R., and Burns, D.L. 1992. FASEB J.6, 2684.
Zhu, J., et al. 1992. J. Pharmacol. Exp. Therap.263, 1479
Kaslow, H.R., et al. 1987. Biochemistry26, 123.
Hewlett, E.L., et al. 1983. Infect. Immun.40, 1198.
Moss, J., et al. 1983. J. Biol. Chem.258, 11879.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany